Figure 6. AB4 inactivates AKT-STAT1-PRDX1-NF-κB signaling in macrophages. BMDMs (A ) and differentiated THP-1 cells (B ) were pretreated with AB4 (50, 100, and 200μM) for 4h, and then cultured with LPS (1μg/ml) for 6h. The protein of the indicated molecule was detected by Western Blot. BMDMs were pretreated with AB4 (200μM) or NF-κB inhibitor JSH-23 (25μM) for 4h and then cultured with LPS (1μg/ml) for 6h. The protein of the indicated molecule was detected by Western Blot (C ), and the mRNA expression of NLRP3, IL-1β, and IL-18 was analyzed by qPCR (D ). (E ) BMDMs were pretreated with AB4 (200μM) or AKT inhibitor MK2206 (20μM) for 4h and then cultured with LPS (1μg/ml) for 6h. The protein of the indicated molecule was detected by Western Blot. Data are presented as mean ± SD.**P < 0.01 vs. Control group;#P < 0.05, ##P < 0.01 vs. LPS group. (F ) BMDMs were pretreated with AB4 (200μM) for 4h or AKT agonist SC79 (20μM) for 6h and then cultured with LPS (1μg/ml) for 6h. The protein of the indicated molecule was detected by Western Blot. Data are presented as mean ± SD.**P < 0.01 LPS+SC79+AB4 vs. LPS+AB4 group. (G ) WT mice were subjected to DSS-induced colitis. The protein expression of the indicated molecule in colons was detected by Western Blot. Data are presented as mean ± SD. **P < 0.01 vs.Normal group; #P < 0.05,##P < 0.01 vs. DSS group.